» Articles » PMID: 19665479

Smoking, Nicotine and Neuropsychiatric Disorders

Overview
Date 2009 Aug 12
PMID 19665479
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Tobacco smoking is an extremely addictive and harmful form of nicotine (NIC) consumption, but unfortunately also the most prevalent. Although disproportionately high frequencies of smoking and its health consequences among psychiatric patients are widely known, the neurobiological background of this epidemiological association is still obscure. The diverse neuroactive effects of NIC and some other major tobacco smoke constituents in the central nervous system may underlie this association. This present paper summarizes the pharmacology of NIC and its receptors (nAChR) based on a systematic review of the literature. The role of the brain's reward system(s) in NIC addiction and the results of functional and structural neuroimaging studies on smoking-related states and behaviors (i.e. dependence, craving, withdrawal) are also discussed. In addition, the epidemiological, neurobiological, and genetic aspects of smoking in several specific neuropsychiatric disorders are reviewed and the clinical relevance of smoking in these disease states addressed.

Citing Articles

Chronic nicotine exposure induces molecular and transcriptomic endophenotypes associated with mood and anxiety disorders in a cerebral organoid neurodevelopmental model.

Proud E, Rodriguez-Ruiz M, Gummerson D, Vanin S, Hardy D, Rushlow W Front Pharmacol. 2025; 15:1473213.

PMID: 39764466 PMC: 11701148. DOI: 10.3389/fphar.2024.1473213.


Preventive Effects of Crocin, a Key Carotenoid Component in Saffron, Against Nicotine-Triggered Neurodegeneration in Rat Hippocampus: Possible Role of Autophagy and Apoptosis.

Gholami M, Klionsky D, Motaghinejad M Int J Prev Med. 2024; 15:46.

PMID: 39539579 PMC: 11559686. DOI: 10.4103/ijpvm.ijpvm_41_23.


The double-edged nature of nicotine: toxicities and therapeutic potentials.

Cao Y, Sun J, Wang X, Zhang X, Tian H, Huang L Front Pharmacol. 2024; 15:1427314.

PMID: 39206262 PMC: 11350241. DOI: 10.3389/fphar.2024.1427314.


Smoking affects symptom improvement in schizophrenia: a prospective longitudinal study of male patients with first-episode schizophrenia.

Mu X, Wu W, Wang S, Su X, Guan H, Guan X Schizophrenia (Heidelb). 2024; 10(1):34.

PMID: 38491003 PMC: 10943037. DOI: 10.1038/s41537-024-00449-1.


Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study.

Gao Z, Xiu M, Liu J, Wu F, Zhang X Curr Neuropharmacol. 2023; 22(10):1733-1741.

PMID: 37859307 PMC: 11284715. DOI: 10.2174/1570159X22666231019105328.